WebAug 5, 2024 · SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today ... WebExec / Sr Dir, Clinical Research Hematology/Oncology Gilead Sciences 2016 - Mar 2024 5 years. Dir / Assoc Dir ... Vice President Clinical Development …
Sierra Oncology Stock Soars After $1.9 Billion Takeover by Glaxo
WebNov 22, 2024 · Sierra Oncology, Inc. ClinicalTrials.gov Identifier: NCT04173494 Other Study ID Numbers: SRA-MMB-301 : First Posted: November 22, 2024 Key Record Dates: Results First Posted: December 22, 2024: Last Update Posted: December 22, 2024 Last Verified: December 2024 Individual Participant Data (IPD) Sharing Statement: WebAug 23, 2024 · Fenwick & West represented Sierra Oncology, Inc. (Nasdaq: SRRA), a leading clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, in its asset purchase of the drug candidate momelotinib from Gilead Sciences, Inc. (Nasdaq: … clean winner
Promising results from onetime Gilead cancer drug pushes Sierra ...
WebAug 6, 2024 · Sierra Oncology excludes a non-cash charge pertaining to the changes in fair value of an obligation to issue common stock and a warrant to Gilead because it is a non-cash expense. Sierra Oncology excludes non-cash stock-based compensation expense from its non-GAAP financial measures because it believes that excluding this item provides … WebJan 25, 2024 · Sierra Oncology’s bet on Gilead Sciences castoff momelotinib has paid off. … WebJan 25, 2024 · If Nick Glover were still chief executive of Sierra Oncology he would today be living the biotech dream. Having sold his previous company, YM Biosciences, to Gilead for $510m he then paid just $3m to buy back its lead asset, momelotinib, for his new company, Sierra; today, in Sierra’s hands, that lead asset scored in a pivotal myelofibrosis study. cleanwipe_14.3.558.1000